Coverage
Filings
| Filing | Date |
|---|---|
| Final Results | 29 Jan 2009 |
| Treasury Stock | 5 Jan 2009 |
| Transaction in Own Shares | 22 Dec 2008 |
| Transaction in Own Shares | 15 Dec 2008 |
| Transaction in Own Shares | 8 Dec 2008 |
| Director/PDMR Shareholding | 4 Dec 2008 |
| Transaction in Own Shares | 1 Dec 2008 |
| Transaction in Own Shares | 24 Nov 2008 |
| Research Update |
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 18 Nov 2008 |
| Transaction in Own Shares | 17 Nov 2008 |
| Transaction in Own Shares | 10 Nov 2008 |
| Miscellaneous | 7 Nov 2008 |